Patient advocates emphasize that people rely on these coupons and discount cards to secure their drugs. “It is the way people afford their medications, especially brand name medications that are more expensive,” said Carl Schmid, executive director of HIV+Hepatitis Policy Institute. Schmid cited data from the prescription drug research firm IQVIA Holdings that showed patients received nearly $19 billion last year in copay assistance from drug manufacturers.
LGBTQ agenda: State of HIV care report finds workforce burnout, PrEP awareness are persistent issues
Carl Schmid, a gay man who is the executive director of the Washington, D.C.-based HIV + Hepatitis Policy Institute, concurred with the findings about burnout.HIV providers, like so many others providing health care, are burning out and aging,” Schmid stated. “We need innovative ways to provide HIV care and prevention services. One such way is permitting pharmacists, who are located in all parts of the country, to be allowed to offer some services. California has taken some steps in this arena, and other states are also considering it.”
PrEP has revolutionized the war on HIV—but barriers to access remain
Nationally, about 85,000 people are getting PrEP through community health centers, Carl Schmid said. “Unfortunately, the Republicans in the Congress on the House side have zeroed out that program,” Schmid said. “The Senate has that funding for it, it’s $147 million. But they zeroed out all the Ending the HIV Epidemic funding that impacts North Carolina and 57 jurisdictions. The Senate is actually keeping that money, but, you know, we are facing the possibility of it going away.”
Biden defends Trump-era drug pricing rule on copay accumulators
The Biden administration is appealing a court ruling against a Trump-era regulation that aimed to protect the way health insurance companies handle some prescription drug costs—a rare moment of harmony between the two administration’s approaches to drug pricing reform.
Copay accumulators get a reprieve: Commercial plans’ use will not be restricted by CMS–yet
US Health and Human Service Department questions recent federal court decision striking down the government’s policy of allowing plans to broadly exclude manufacturer copay assistance from counting toward patient deductibles or out-of-pocket maximums.